| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Spero Therapeutics, Inc.: Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference | 2 | GlobeNewswire (USA) | ||
| Mi | Spero Therapeutics Inc reports results for the quarter ended in March - Earnings Summary | 1 | Reuters | ||
| Mi | Spero Therapeutics, Inc.: Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update | 287 | GlobeNewswire (Europe) | On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients, expected in 2H 2024Enrollment ongoing in PIVOT-PO... ► Artikel lesen | |
| 08.05. | Spero Therapeutics, Inc.: Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024 | 3 | GlobeNewswire (USA) | ||
| 01.05. | Spero Therapeutics, Inc.: Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 50 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments... ► Artikel lesen | |
| 29.03. | Spero Therapeutics, Inc. - 8-K, Current Report | 7 | SEC Filings | ||
| 15.03. | Spero Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 14.03. | Spero Therapeutics Inc reports results for the quarter ended in December - Earnings Summary | 12 | Reuters | ||
| 13.03. | Spero Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 13.03. | Spero Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.03. | Spero Therapeutics, Inc.: Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update | 547 | GlobeNewswire (Europe) | On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients, expected in 2H 2024Initiated enrollment in PIVOT-PO... ► Artikel lesen | |
| 06.03. | Spero Therapeutics, Inc.: Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024 | 5 | GlobeNewswire (USA) | ||
| 28.02. | Spero Therapeutics, Inc.: Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections | 793 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments... ► Artikel lesen | |
| 26.02. | Spero Therapeutics, Inc.: Spero Therapeutics to Present at Cowen's 44th Annual Healthcare Conference | 4 | GlobeNewswire (USA) | ||
| 31.01. | Spero Therapeutics, Inc.: Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 18 | GlobeNewswire (USA) | ||
| 05.01. | Spero Therapeutics, Inc.: Spero Therapeutics Provides Corporate Update and 2024 Outlook | 396 | GlobeNewswire (Europe) | In 2H 2024, expect to provide Phase 2a topline proof-of-concept data from our wholly-owned lead program SPR720 in NTM-PD patients Initiated dosing in PIVOT-PO Phase 3 trial for tebipenem HBr in cUTI... ► Artikel lesen | |
| 02.01. | Spero Therapeutics, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 02.01. | Spero Therapeutics, Inc.: Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections | 234 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| GAMESTOP | 1.748 |
| EVOTEC | 1.401 |
| TUI | 1.093 |
| NVIDIA | 908 |
| PLUG POWER | 755 |
| BAYER | 654 |
| RHEINMETALL | 646 |
| NEL | 638 |
| SIEMENS ENERGY | 624 |
| BARRICK GOLD | 508 |
| RENK GROUP | 488 |
| DEUTSCHE BANK | 477 |
| AIXTRON SE | 468 |
| AMC ENTERTAINMENT | 456 |
| BYD | 452 |
| MERCEDES-BENZ | 436 |
| VOLKSWAGEN | 436 |
| COMMERZBANK | 415 |
| DEUTSCHE LUFTHANSA | 386 |
| SUPER MICRO COMPUTER | 379 |
| HEIDELBERGER DRUCK | 369 |
| TESLA | 364 |
| RWE | 329 |
| ALLIANZ | 323 |
| BASF | 306 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
